Jagsonpal Pharmaceuticals is currently trading at its upper circuit limit of Rs. 245.55, up by 40.90 points or 19.99% from its previous closing of Rs. 204.65 on the BSE.
The scrip opened at Rs. 224.70 and has touched a high and low of Rs. 244.50 and Rs. 218.50 respectively. So far 129571 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 245.55 on 22-Feb-2022 and a 52 week low of Rs. 75.00 on 15-Apr-2021.
Last one week high and low of the scrip stood at Rs. 245.55 and Rs. 167.40 respectively. The current market cap of the company is Rs. 636.74 crore.
The promoters holding in the company stood at 70.34%, while Institutions and Non-Institutions held 0.12% and 29.54% respectively.
Jagsonpal Pharmaceuticals has entered into an agreement with Suvinys Developers for supply of product Dydrogesterone. Suvinys Developers will supply Dydrogesterone to Jagsonpal Pharmaceuticals as per the terms and conditions as mentioned in the agreement.
Jagsonpal Pharmaceutical is among India’s premiere pharmaceutical companies. The company has substantial research and development, manufacturing, marketing and distribution facilities.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |